Financial Consulate’s Pacira BioSciences PCRX Stock Holding History

Financial Consulate’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$258	–	1420
2025 Q3	$258	Buy	+10	New	+$246	﹤0.01%	1125

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Consulate's PCRX Position: Q4 2025 in Review

Financial Consulate sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 10 shares — an estimated $258 sold.

Financial Consulate first reported a position in PCRX in Q3 2025 and held it in 1 quarter. The position peaked at $258 in Q3 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Financial Consulate reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Financial Consulate sold 10 Pacira BioSciences shares in Q4 2025, an estimated $258.
Financial Consulate first reported a position in Pacira BioSciences in Q3 2025 and held it in 1 quarter.
Financial Consulate's Pacira BioSciences position peaked at $258 in Q3 2025.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Financial Consulate's 13F filing for Q4 2025, filed 22 Jan 2026.